INTRA CELLULAR THERAPIES INC's ticker is ITCI and the CUSIP is 46116X101. A total of 241 filers reported holding INTRA CELLULAR THERAPIES INC in Q1 2022. The put-call ratio across all filers is 0.55 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $879,279 | -17.7% | 16,880 | 0.0% | 0.03% | -21.6% |
| Q2 2023 | $1,068,842 | +27.5% | 16,880 | +9.0% | 0.04% | +23.3% |
| Q1 2023 | $838,242 | -47.3% | 15,480 | -48.5% | 0.03% | -50.8% |
| Q4 2022 | $1,591,834 | +6.3% | 30,080 | -6.5% | 0.06% | -1.6% |
| Q3 2022 | $1,497,000 | -18.5% | 32,180 | 0.0% | 0.06% | -13.9% |
| Q2 2022 | $1,837,000 | -6.7% | 32,180 | 0.0% | 0.07% | +9.1% |
| Q1 2022 | $1,969,000 | +16.9% | 32,180 | 0.0% | 0.07% | +22.2% |
| Q4 2021 | $1,684,000 | -71.4% | 32,180 | -79.7% | 0.05% | -73.3% |
| Q3 2021 | $5,897,000 | -15.9% | 158,180 | -7.9% | 0.20% | -16.5% |
| Q2 2021 | $7,009,000 | +20.3% | 171,700 | 0.0% | 0.24% | +12.0% |
| Q1 2021 | $5,826,000 | -20.8% | 171,700 | -25.8% | 0.22% | -35.5% |
| Q4 2020 | $7,355,000 | +117.2% | 231,300 | +75.2% | 0.34% | +91.4% |
| Q3 2020 | $3,387,000 | -6.4% | 132,000 | -6.4% | 0.18% | -13.4% |
| Q2 2020 | $3,619,000 | – | 141,000 | – | 0.20% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Ally Bridge Group (NY) LLC | 175,000 | $9,115,750 | 10.70% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 317,856 | $16,547,583 | 5.57% |
| Deep Track Capital, LP | 2,600,000 | $135,434,000 | 5.23% |
| SUVRETTA CAPITAL MANAGEMENT, LLC | 1,369,849 | $71,355,434 | 3.86% |
| SILVERARC CAPITAL MANAGEMENT, LLC | 208,730 | $10,872,746 | 3.30% |
| DCF Advisers, LLC | 107,157 | $5,581,808 | 3.04% |
| Bellevue Group AG | 3,170,250 | $165,138,323 | 2.66% |
| Vahanian & Associates Financial Planning Inc. | 15,217 | $792,654 | 2.55% |
| Iron Triangle Partners LP | 330,549 | $17,218,297 | 2.52% |
| TANG CAPITAL MANAGEMENT LLC | 300,000 | $15,627,000 | 2.20% |